Investment Thesis
Why ASD-002. Why Now.
01
Unmet Need
Oral clopidogrel requires 2 to 5 hours to achieve therapeutic platelet inhibition. In emergency PCI, that window is clinically unacceptable. 570,000–950,000 PCI patients per year, who are intubated, sedated, or NPO, cannot receive oral P2Y12 agents. No injectable P2Y12 clopidogrel alternative has ever been approved. This patient population has no option.
02
Solved IV Formulation
Ascendia's EmulSol® nanoemulsion overcame the chemical instability challenge that defeated every prior program — simultaneous hydrolysis, oxidation, and chiral degradation protection without organic solvents.
03
De-Risked Pathway
505(b)(2) NDA referencing oral clopidogrel NDA 20839. Three Phase 1 studies, ~180 healthy volunteers, no Phase 2/3 required. 64.5% first-cycle approval rate.
Pipeline
Four Programs. Two Platforms.
Preclin.
IND
Ph 1a
Ph 1b
Ph 2
Ph 3
NDA
Approved
ASD-002
Coronary PCI · PAD Endovascular
ASD-005
Heart Failure / Post-MI · NPO/Intubated
ASD-004
Chronic Dry Eye Disease
ASD-002 Oral
Dysphagia · Pediatric · NG Tube
Active / Complete
Current Stage
Planned
$23.7Bn
US P2Y12 Inhibitor Market
64.5%
505(b)(2) first-cycle FDA approval rate
3.8M
US Percutaneous Coronary Intervention (PCI) annually
>1.3M
US Peripheral Vascular Intervention (PVI) annually